An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Amneal Pharmaceuticals to release Q3 2023 financial results
Positive
Amneal Pharmaceuticals, Inc. will release its third quarter 2023 financial results on November 7, 2023, prior to market open.
Negative
None.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call.
To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this link. The access code for the call is 605508.
A replay of the conference call will be posted shortly after the call and will be available for seven days.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.
When will Amneal Pharmaceuticals release its Q3 2023 financial results?
Amneal Pharmaceuticals will release its Q3 2023 financial results on November 7, 2023, prior to market open.
Where can I access the financial results and live webcast?
The financial results and live webcast will be accessible through the Investor Relations section of Amneal Pharmaceuticals' website at https://investors.amneal.com.
How can I register for the conference call?
You can register for the conference call by clicking the provided link in the PR.
What is the access code for the call?
The access code for the call is 605508.
Will there be a replay of the conference call?
Yes, a replay of the conference call will be posted shortly after the call and will be available for seven days.
